Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers
Rabeprazole 10mg b.i.d. is often administered as therapy for eradication of Helicobacter pylori (H. pylori) and is also proposed as therapy for refractory gastro-oesophageal reflux disease. However, there has not been a comprehensive assessment of its acid-suppressive effects. To compare the acid-su...
Gespeichert in:
| Veröffentlicht in: | Digestive and liver disease 2006-11, Vol.38 (11), p.802-808 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 808 |
|---|---|
| container_issue | 11 |
| container_start_page | 802 |
| container_title | Digestive and liver disease |
| container_volume | 38 |
| creator | Shimatani, T Moriwaki, M Xu, J Tazuma, S Inoue, M |
| description | Rabeprazole 10mg b.i.d. is often administered as therapy for eradication of Helicobacter pylori (H. pylori) and is also proposed as therapy for refractory gastro-oesophageal reflux disease. However, there has not been a comprehensive assessment of its acid-suppressive effects.
To compare the acid-suppressive effects of rabeprazole 10mg b.i.d. with 20mg b.i.d. considering H. pylori status.
Thirteen H. pylori-negative and eleven H. pylori-positive Japanese CYP2C19 extensive metabolisers (3.0, >4.0, >5.0, >6.0, and >7.0 for 24h, no significant differences were observed between the two doses in either H. pylori-negative or H. pylori-positive subjects. At either dose, these parameters were significantly higher in H. pylori-positive subjects than in H. pylori-negative subjects. Nocturnal acid breakthrough occurred in seven and two of the thirteen H. pylori-negative subjects and one and two of the eleven H. pylori-positive subjects at each dose, respectively.
The effects of rabeprazole 10mg b.i.d. were equal to those of 20mg b.i.d. in H. pylori-positive subjects; whereas in H. pylori-negative subjects, 20mg b.i.d. was superior for prevention of nocturnal acid breakthrough. |
| doi_str_mv | 10.1016/j.dld.2006.06.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68908595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68908595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2105-a95bda6b08b29fd4df50384c08df0e60708acd907d58b2482d3d71fc0b2bbfd23</originalsourceid><addsrcrecordid>eNpFUctuFDEQ9AFEQsIHcEE-cZtN27Oe9XCLVoSAIpFDcuBk-dFeeeUZG3uWsHwOX8pMshJSS_1QVXW3ipD3DFYMWHe1X7noVhygWy0B_BU5Z6KHRnZCnpG3te7nIesEvCFnrJPrFjbinPy9tsE19ZBzwVrDL6ToPdqp0uRp0QZz0X9SxE_UpiHrEsYdZTDsqB4d5UsxPQWL1OkQjzSM9JvOesSK9BZjsMloO2Gh-RhTCc2IOz0tSxZ2k1MNz932xz3fsp7i7wnH5yMGnLRJMVQs9ZK89jpWfHfKF-Tx5vPD9ra5-_7l6_b6rrGcgWh0L4zTnQFpeO_d2nkBrVxbkM4DdrABqa3rYePEjFhL7lq3Yd6C4cZ4x9sL8vFFN5f084B1UkOoFmOc_0mHqjrZgxS9mIHsBWhLqrWgV7mEQZejYqAWM9RezWaoxQy1BCziH07iBzOg-884OdH-A3Ggixc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68908595</pqid></control><display><type>article</type><title>Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Shimatani, T ; Moriwaki, M ; Xu, J ; Tazuma, S ; Inoue, M</creator><creatorcontrib>Shimatani, T ; Moriwaki, M ; Xu, J ; Tazuma, S ; Inoue, M</creatorcontrib><description>Rabeprazole 10mg b.i.d. is often administered as therapy for eradication of Helicobacter pylori (H. pylori) and is also proposed as therapy for refractory gastro-oesophageal reflux disease. However, there has not been a comprehensive assessment of its acid-suppressive effects.
To compare the acid-suppressive effects of rabeprazole 10mg b.i.d. with 20mg b.i.d. considering H. pylori status.
Thirteen H. pylori-negative and eleven H. pylori-positive Japanese CYP2C19 extensive metabolisers (<35 years).
Intragastric pH was measured for 24h three times in a randomised manner; on day 7 of the repeated administration of rabeprazole 10mg b.i.d. or 20mg b.i.d., or a placebo.
In median intragastric pH value and percent time of pH>3.0, >4.0, >5.0, >6.0, and >7.0 for 24h, no significant differences were observed between the two doses in either H. pylori-negative or H. pylori-positive subjects. At either dose, these parameters were significantly higher in H. pylori-positive subjects than in H. pylori-negative subjects. Nocturnal acid breakthrough occurred in seven and two of the thirteen H. pylori-negative subjects and one and two of the eleven H. pylori-positive subjects at each dose, respectively.
The effects of rabeprazole 10mg b.i.d. were equal to those of 20mg b.i.d. in H. pylori-positive subjects; whereas in H. pylori-negative subjects, 20mg b.i.d. was superior for prevention of nocturnal acid breakthrough.</description><identifier>ISSN: 1590-8658</identifier><identifier>DOI: 10.1016/j.dld.2006.06.002</identifier><identifier>PMID: 16843075</identifier><language>eng</language><publisher>Netherlands</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage ; Adult ; Anti-Ulcer Agents - administration & dosage ; Aryl Hydrocarbon Hydroxylases - genetics ; Asian Continental Ancestry Group - genetics ; Cross-Over Studies ; Cytochrome P-450 CYP2C19 ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Gastric Acidity Determination ; Gastroesophageal Reflux - drug therapy ; Gastroesophageal Reflux - microbiology ; Genotype ; Helicobacter Infections - drug therapy ; Helicobacter Infections - genetics ; Helicobacter pylori ; Humans ; Hydrogen-Ion Concentration ; Japan ; Mixed Function Oxygenases - genetics ; Pepsinogen A - blood ; Pepsinogen C - blood ; Polymorphism, Genetic ; Prospective Studies ; Proton-Translocating ATPases - antagonists & inhibitors ; Rabeprazole ; Stomach - chemistry</subject><ispartof>Digestive and liver disease, 2006-11, Vol.38 (11), p.802-808</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2105-a95bda6b08b29fd4df50384c08df0e60708acd907d58b2482d3d71fc0b2bbfd23</citedby><cites>FETCH-LOGICAL-c2105-a95bda6b08b29fd4df50384c08df0e60708acd907d58b2482d3d71fc0b2bbfd23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16843075$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimatani, T</creatorcontrib><creatorcontrib>Moriwaki, M</creatorcontrib><creatorcontrib>Xu, J</creatorcontrib><creatorcontrib>Tazuma, S</creatorcontrib><creatorcontrib>Inoue, M</creatorcontrib><title>Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers</title><title>Digestive and liver disease</title><addtitle>Dig Liver Dis</addtitle><description>Rabeprazole 10mg b.i.d. is often administered as therapy for eradication of Helicobacter pylori (H. pylori) and is also proposed as therapy for refractory gastro-oesophageal reflux disease. However, there has not been a comprehensive assessment of its acid-suppressive effects.
To compare the acid-suppressive effects of rabeprazole 10mg b.i.d. with 20mg b.i.d. considering H. pylori status.
Thirteen H. pylori-negative and eleven H. pylori-positive Japanese CYP2C19 extensive metabolisers (<35 years).
Intragastric pH was measured for 24h three times in a randomised manner; on day 7 of the repeated administration of rabeprazole 10mg b.i.d. or 20mg b.i.d., or a placebo.
In median intragastric pH value and percent time of pH>3.0, >4.0, >5.0, >6.0, and >7.0 for 24h, no significant differences were observed between the two doses in either H. pylori-negative or H. pylori-positive subjects. At either dose, these parameters were significantly higher in H. pylori-positive subjects than in H. pylori-negative subjects. Nocturnal acid breakthrough occurred in seven and two of the thirteen H. pylori-negative subjects and one and two of the eleven H. pylori-positive subjects at each dose, respectively.
The effects of rabeprazole 10mg b.i.d. were equal to those of 20mg b.i.d. in H. pylori-positive subjects; whereas in H. pylori-negative subjects, 20mg b.i.d. was superior for prevention of nocturnal acid breakthrough.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage</subject><subject>Adult</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Cross-Over Studies</subject><subject>Cytochrome P-450 CYP2C19</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Gastric Acidity Determination</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Gastroesophageal Reflux - microbiology</subject><subject>Genotype</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - genetics</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Japan</subject><subject>Mixed Function Oxygenases - genetics</subject><subject>Pepsinogen A - blood</subject><subject>Pepsinogen C - blood</subject><subject>Polymorphism, Genetic</subject><subject>Prospective Studies</subject><subject>Proton-Translocating ATPases - antagonists & inhibitors</subject><subject>Rabeprazole</subject><subject>Stomach - chemistry</subject><issn>1590-8658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFUctuFDEQ9AFEQsIHcEE-cZtN27Oe9XCLVoSAIpFDcuBk-dFeeeUZG3uWsHwOX8pMshJSS_1QVXW3ipD3DFYMWHe1X7noVhygWy0B_BU5Z6KHRnZCnpG3te7nIesEvCFnrJPrFjbinPy9tsE19ZBzwVrDL6ToPdqp0uRp0QZz0X9SxE_UpiHrEsYdZTDsqB4d5UsxPQWL1OkQjzSM9JvOesSK9BZjsMloO2Gh-RhTCc2IOz0tSxZ2k1MNz932xz3fsp7i7wnH5yMGnLRJMVQs9ZK89jpWfHfKF-Tx5vPD9ra5-_7l6_b6rrGcgWh0L4zTnQFpeO_d2nkBrVxbkM4DdrABqa3rYePEjFhL7lq3Yd6C4cZ4x9sL8vFFN5f084B1UkOoFmOc_0mHqjrZgxS9mIHsBWhLqrWgV7mEQZejYqAWM9RezWaoxQy1BCziH07iBzOg-884OdH-A3Ggixc</recordid><startdate>200611</startdate><enddate>200611</enddate><creator>Shimatani, T</creator><creator>Moriwaki, M</creator><creator>Xu, J</creator><creator>Tazuma, S</creator><creator>Inoue, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200611</creationdate><title>Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers</title><author>Shimatani, T ; Moriwaki, M ; Xu, J ; Tazuma, S ; Inoue, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2105-a95bda6b08b29fd4df50384c08df0e60708acd907d58b2482d3d71fc0b2bbfd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage</topic><topic>Adult</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Cross-Over Studies</topic><topic>Cytochrome P-450 CYP2C19</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Gastric Acidity Determination</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Gastroesophageal Reflux - microbiology</topic><topic>Genotype</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - genetics</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Japan</topic><topic>Mixed Function Oxygenases - genetics</topic><topic>Pepsinogen A - blood</topic><topic>Pepsinogen C - blood</topic><topic>Polymorphism, Genetic</topic><topic>Prospective Studies</topic><topic>Proton-Translocating ATPases - antagonists & inhibitors</topic><topic>Rabeprazole</topic><topic>Stomach - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimatani, T</creatorcontrib><creatorcontrib>Moriwaki, M</creatorcontrib><creatorcontrib>Xu, J</creatorcontrib><creatorcontrib>Tazuma, S</creatorcontrib><creatorcontrib>Inoue, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive and liver disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimatani, T</au><au>Moriwaki, M</au><au>Xu, J</au><au>Tazuma, S</au><au>Inoue, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers</atitle><jtitle>Digestive and liver disease</jtitle><addtitle>Dig Liver Dis</addtitle><date>2006-11</date><risdate>2006</risdate><volume>38</volume><issue>11</issue><spage>802</spage><epage>808</epage><pages>802-808</pages><issn>1590-8658</issn><abstract>Rabeprazole 10mg b.i.d. is often administered as therapy for eradication of Helicobacter pylori (H. pylori) and is also proposed as therapy for refractory gastro-oesophageal reflux disease. However, there has not been a comprehensive assessment of its acid-suppressive effects.
To compare the acid-suppressive effects of rabeprazole 10mg b.i.d. with 20mg b.i.d. considering H. pylori status.
Thirteen H. pylori-negative and eleven H. pylori-positive Japanese CYP2C19 extensive metabolisers (<35 years).
Intragastric pH was measured for 24h three times in a randomised manner; on day 7 of the repeated administration of rabeprazole 10mg b.i.d. or 20mg b.i.d., or a placebo.
In median intragastric pH value and percent time of pH>3.0, >4.0, >5.0, >6.0, and >7.0 for 24h, no significant differences were observed between the two doses in either H. pylori-negative or H. pylori-positive subjects. At either dose, these parameters were significantly higher in H. pylori-positive subjects than in H. pylori-negative subjects. Nocturnal acid breakthrough occurred in seven and two of the thirteen H. pylori-negative subjects and one and two of the eleven H. pylori-positive subjects at each dose, respectively.
The effects of rabeprazole 10mg b.i.d. were equal to those of 20mg b.i.d. in H. pylori-positive subjects; whereas in H. pylori-negative subjects, 20mg b.i.d. was superior for prevention of nocturnal acid breakthrough.</abstract><cop>Netherlands</cop><pmid>16843075</pmid><doi>10.1016/j.dld.2006.06.002</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-8658 |
| ispartof | Digestive and liver disease, 2006-11, Vol.38 (11), p.802-808 |
| issn | 1590-8658 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68908595 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage Adult Anti-Ulcer Agents - administration & dosage Aryl Hydrocarbon Hydroxylases - genetics Asian Continental Ancestry Group - genetics Cross-Over Studies Cytochrome P-450 CYP2C19 Dose-Response Relationship, Drug Drug Administration Schedule Gastric Acidity Determination Gastroesophageal Reflux - drug therapy Gastroesophageal Reflux - microbiology Genotype Helicobacter Infections - drug therapy Helicobacter Infections - genetics Helicobacter pylori Humans Hydrogen-Ion Concentration Japan Mixed Function Oxygenases - genetics Pepsinogen A - blood Pepsinogen C - blood Polymorphism, Genetic Prospective Studies Proton-Translocating ATPases - antagonists & inhibitors Rabeprazole Stomach - chemistry |
| title | Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A30%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acid-suppressive%20effects%20of%20rabeprazole:%20comparing%2010mg%20and%2020mg%20twice%20daily%20in%20Japanese%20Helicobacter%20pylori-negative%20and%20-positive%20CYP2C19%20extensive%20metabolisers&rft.jtitle=Digestive%20and%20liver%20disease&rft.au=Shimatani,%20T&rft.date=2006-11&rft.volume=38&rft.issue=11&rft.spage=802&rft.epage=808&rft.pages=802-808&rft.issn=1590-8658&rft_id=info:doi/10.1016/j.dld.2006.06.002&rft_dat=%3Cproquest_cross%3E68908595%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68908595&rft_id=info:pmid/16843075&rfr_iscdi=true |